Long-Term Efficacy and Safety of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from RAMP 201-Video Recording

Video Transcription

Video Summary

The discussion reviewed long-term results from the RAMP 201 study of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer. The combination showed durable benefit, with an overall response rate of 31% and 44% in KRAS-mutant tumors. At nearly 25 months of follow-up, median duration of response was 31.1 months, and median progression-free survival was 19.6 months in KRAS-mutant and 12.7 months in KRAS wild-type disease. No new safety signals emerged, and toxicities were usually front-loaded rather than cumulative. Common side effects included rash, edema, diarrhea, nausea, and elevated CPK, often manageable with dose holds, supportive care, and prophylaxis such as antibiotics and sun protection. The speakers emphasized that KRAS testing should be done on tumor tissue, not blood. They also discussed ongoing and future studies, including a phase 3 confirmatory trial and an earlier-line neoadjuvant/adjuvant study, while noting that sequencing and biomarker testing remain important in practice.

Keywords

avutometinib

defactinib

low-grade serous ovarian cancer

KRAS mutation

progression-free survival

phase 3 trial